Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib plus chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia
ChiCTR-ONC-12002469Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nilotinib in acute lymphoblastic leukemia (ALL), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Complete remission rate and Overall survival. Started Sep 2011; status: recruiting.
02
Drugs
nilotinib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on ChiCTR-ONC-12002469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-ONC-12002469.